The Tuberculosis Drugs Market Is Growing Rapidly With The Global Alliance For TB Drug Development Gaining The U.S. FDA Approval For Its Pretomanid Tablets
Tuberculosis (TB) is the most prevalent pulmonary tuberculosis disease. Because of the very difficult and lengthy period of survival after becoming infected with pulmonary tuberculosis (PTC) and the associated often severe pulmonary and immune system disorders, the management of tuberculosis often revolves around early initiation of treatment. One of the primary factors fueling growth of the market in discussion is rapidly growing cases of tuberculosis worldwide. As per the World Health Organization (WHO), in 2019, around 1.4 million people died from tuberculosis worldwide with around 10 million people being diagnosed with the same. Such massive incidence of tuberculosis cases across the globe could potentially stimulate the tuberculosis drugs market.
As far as regional impact is
considered, North America seems to be exhibiting significant traction in the
tuberculosis drugs market. This can be attributed to the lower cost of TB drugs
in the region. On the contrary, Asia Pacific is registering a positive outlook
with rising prevalence of tuberculosis cases in India and other emerging
economies. Recently, in August 2019, The Global Alliance for TB Drug
Development (TB Alliance) received the U.S. Food and Drug Administration (FDA)
approval for Pretomanid Tablets for the treatment of a specific type of highly
treatment-resistant TB of lungs.
The core set of pulmonary
tuberculosis drugs are saldol, bacrostat, rifampicin, or dioxin. These
medications have different actions in different animals and humans. These drugs
also differ in their metabolism in terms of frequency of release and
elimination. That being said, there are certain challenges involved in the
market that could limit future development. For instance, tuberculosis drugs
have adverse effects on the patient such as itchy skin, upset stomach, nausea,
rashes, diarrhea, and changes in eyesight. Besides, the high cost of XDR and
MDR TB drugs could impede growth of the tuberculosis drugs market.
Recently, another interesting
tuberculosis drug, i.e. muribethalin, has been discovered. This novel compound
acts on tuberculosis-resistant strains of the infection by preventing their
ability to digest protein. Studies in the field of MDR-TB and tuberculosis are
still in their initial phase, although the developments so far indicate that
the search for more powerful drugs is still going on. Since there is a high
incidence of tuberculosis cases worldwide, government organizations in many
countries have taken proactive initiatives to raise tuberculosis awareness
among people. These initiatives include vaccination drives, additional funding
for awareness campaigns, and the availability of high-quality drugs. For
instance, in 2017, the Government of India announced the plan to eliminate TB
by 2025. Such proactive initiatives could potentially augment growth of the
tuberculosis drugs market.
Comments
Post a Comment